论文部分内容阅读
通过90例肾移植病人进行三联与二联治疗的分析,认为三联免疫抑制剂应用在其肾毒性、药物费用、一年人/肾存活率和感染等方面优于二联免疫抑制剂的应用。
The analysis of triple and dual therapy in 90 renal transplant patients suggests that the use of triple immunosuppressive agents is superior to that of di immunosuppressive agents in aspects of nephrotoxicity, drug cost, one-year human / kidney survival and infection.